This is the true story…of Real-World Evidence (RWE) in COVID-19 Therapeutics

11:05 AM - 11:50 AM (EDT), Tuesday, June 15, 2021
Search General Info
Search Education
Search Partnering Companies

The onset of COVID-19 required rapid development and availability of potential treatments.  In the early weeks of the pandemic, the FDA looked to advanced analytical techniques and announced collaborations with public and private partners to collect and analyze a variety of real-world data sources. Now, take a look back at how the application of real-world evidence (RWE) was used to advance emergency use authorization and/or approval of COVID-19 therapeutics –  a successful example of bringing together multiple stakeholders from industry, the federal government, and healthcare technology.

Moderator
photo
Senior Director, Science & Regulatory Affairs
Biotechnology Innovation Organization
Speakers
photo
Vice President, Medical Affairs Research
Gilead Sciences
photo
Chief Executive Officer
Aetion, Inc.
photo
Senior Director, Science & Regulatory Affairs
Biotechnology Innovation Organization
photo
Chief Executive Officer
Reagan-Udall Foundation for the FDA